Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Soliris for Generalized MG

Alexion news release; 2017 Oct 23

Alexion Pharmaceuticals, Inc. has announced that the US Food and Drug Administration (FDA) has approved Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive.

Indications: Soliris demonstrated treatment benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms, which can include difficulties seeing, walking, talking, swallowing, and breathing. These patients are at an increased risk of disease exacerbations and crises that may require hospitalization and intensive care and may be life-threatening. They represent approximately 5-10% of all patients with MG.

Dosage/administration: For patients with gMG, Soliris therapy consists of 900 mg weekly for the first 4 weeks, followed by 1,200 mg for the fifth dose 1 week later, then 1,200 mg every 2 weeks thereafter. Soliris should be administered at the recommended dosage regimen time points, or within 2 days of these time points.

Adverse reactions: In patients with gMG who are anti-AchR antibody-positive, the most frequently reported adverse reaction observed in the placebo-controlled clinical study (≥10%) was musculoskeletal pain.


FDA approves Soliris (eculizumab) for the treatment of patients with generalized myasthenia gravis (gMG). [news release]. New Haven, Connecticut: Alexion Pharmaceuticals, Inc. October 23, 2017. Accessed October 30, 2017.

This Week's Must Reads

Potential Limitations of Balance Confidence Scales, Int J MS Care; ePub 2018 Jan 24; Wood, Wajda, et al

Cognitive Phenotypes in MS and Targeted Treatments, J Neurology; ePub 2018 Jan 22; Leavitt, Tosto, et al

Demographic Characteristics in Persons with MS, J Int Neuropsychol Soc; 2018 Feb; Costa, et al

Mercy Evaluation of MS Appropriately Valid, Clin Neuropsychol; ePub 2018 Jan 23; Merz, et al

Walking Speed, Endurance Studied in Persons with MS, J Neurophysiol; ePub 2018 Jan 3; Almuklass, et al

Must Reads in FDA Actions

Riptide Aspiration System Receives FDA Clearance, Medtronic news release; 2018 Jan 16

FDA Approves Vercise Deep Brain Stimulation System, Boston Scientific news release; 2017 Dec 11

FDA Clears Apple Watch Heart Rate Accessory, PharmaLive news release; 2017 Nov 30